File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese

TitleOne-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese
Authors
Issue Date2002
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2002, v. 16 n. 12, p. 2067-2072 How to Cite?
AbstractBackground: We have previously shown that ranitidine bismuth citrate-based, clarithromycin-containing triple therapy achieves a higher eradication rate than proton pump inhibitor-based regimens in areas with a high prevalence of metronidazole resistance. Aim: To evaluate whether this higher efficacy of ranitidine bismuth citrate over proton pump inhibitor can be extended to non-clarithromycin-containing regimens. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either ranitidine bismuth citrate, 400 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, or omeprazole, 20 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, each given twice daily for 1 week, H, pylori eradication was confirmed by 13C-urea breath test 5 weeks later. The side-effects of the treatments were documented. Results: Two hundred and twenty-nine patients were eligible for analysis. By intention-to-treat and per protocol analysis, the eradication rates were 77% and 79%, respectively, in the ranitidine bismuth citrate-amoxicillin-metronidazole group and 77% and 82%, respectively, in the omeprazole-amoxicillin-metronidazole group (P = 0.58 and P = 0.65). However, patients in the omeprazole-amoxicillin-metronidazole group reported a significantly higher incidence of minor side-effects when compared to those in the ranitidine bismuth citrate-amoxicillin-metronidazole group (P = 0.001). Conclusions: Ranitidine bismuth citrate-amoxicillin-metronidazole was equally as effective as omeprazole-amoxicillin-metronidazole triple therapy, and may be considered as an alternative non-clarithromycin-based regimen in the Chinese population.
Persistent Identifierhttp://hdl.handle.net/10722/77433
ISSN
2015 Impact Factor: 6.32
2015 SCImago Journal Rankings: 2.833
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHung, WKen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorWong, GSWen_HK
dc.contributor.authorYip, AWCen_HK
dc.contributor.authorSzeto, MLen_HK
dc.contributor.authorLai, KCen_HK
dc.contributor.authorHu, WHCen_HK
dc.contributor.authorChan, CKen_HK
dc.contributor.authorXia, HHXen_HK
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorFung, FMYen_HK
dc.contributor.authorTong, TSMen_HK
dc.contributor.authorHo, VYKen_HK
dc.contributor.authorLam, SKen_HK
dc.contributor.authorWong, BCYen_HK
dc.date.accessioned2010-09-06T07:31:51Z-
dc.date.available2010-09-06T07:31:51Z-
dc.date.issued2002en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2002, v. 16 n. 12, p. 2067-2072en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77433-
dc.description.abstractBackground: We have previously shown that ranitidine bismuth citrate-based, clarithromycin-containing triple therapy achieves a higher eradication rate than proton pump inhibitor-based regimens in areas with a high prevalence of metronidazole resistance. Aim: To evaluate whether this higher efficacy of ranitidine bismuth citrate over proton pump inhibitor can be extended to non-clarithromycin-containing regimens. Methods: Helicobacter pylori-positive dyspeptic patients were randomized to receive either ranitidine bismuth citrate, 400 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, or omeprazole, 20 mg, amoxicillin, 1000 mg, and metronidazole, 400 mg, each given twice daily for 1 week, H, pylori eradication was confirmed by 13C-urea breath test 5 weeks later. The side-effects of the treatments were documented. Results: Two hundred and twenty-nine patients were eligible for analysis. By intention-to-treat and per protocol analysis, the eradication rates were 77% and 79%, respectively, in the ranitidine bismuth citrate-amoxicillin-metronidazole group and 77% and 82%, respectively, in the omeprazole-amoxicillin-metronidazole group (P = 0.58 and P = 0.65). However, patients in the omeprazole-amoxicillin-metronidazole group reported a significantly higher incidence of minor side-effects when compared to those in the ranitidine bismuth citrate-amoxicillin-metronidazole group (P = 0.001). Conclusions: Ranitidine bismuth citrate-amoxicillin-metronidazole was equally as effective as omeprazole-amoxicillin-metronidazole triple therapy, and may be considered as an alternative non-clarithromycin-based regimen in the Chinese population.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAmoxicillin - therapeutic useen_HK
dc.subject.meshAnti-Bacterial Agents - adverse effects - therapeutic useen_HK
dc.subject.meshAnti-Ulcer Agents - therapeutic useen_HK
dc.subject.meshBismuth - adverse effects - therapeutic useen_HK
dc.subject.meshDrug Therapy, Combinationen_HK
dc.subject.meshDuodenal Ulcer - drug therapy - microbiologyen_HK
dc.subject.meshDyspepsia - drug therapy - microbiologyen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHelicobacter Infections - drug therapy - ethnologyen_HK
dc.subject.meshHelicobacter pylorien_HK
dc.subject.meshHumansen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMetronidazole - therapeutic useen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPenicillins - therapeutic useen_HK
dc.subject.meshRanitidine - adverse effects - analogs & derivatives - therapeutic useen_HK
dc.subject.meshTreatment Outcomeen_HK
dc.titleOne-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chineseen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=16&spage=2067&epage=2072&date=2002&atitle=One-Week+Ranitidine+Bismuth+Citrate,+Amoxicillin+and+Metronidazole+Triple+Therapy+for+the+Treatment+of+Helicobacter+pylori+Infection+in+Chineseen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailWong, BCY:bcywong@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityWong, BCY=rp00429en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1046/j.1365-2036.2002.01384.xen_HK
dc.identifier.pmid12452939-
dc.identifier.scopuseid_2-s2.0-0036909111en_HK
dc.identifier.hkuros80359en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036909111&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume16en_HK
dc.identifier.issue12en_HK
dc.identifier.spage2067en_HK
dc.identifier.epage2072en_HK
dc.identifier.isiWOS:000179529900010-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHung, WK=26027012100en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridWong, GSW=55040777700en_HK
dc.identifier.scopusauthoridYip, AWC=7004871369en_HK
dc.identifier.scopusauthoridSzeto, ML=6602526385en_HK
dc.identifier.scopusauthoridLai, KC=7402135595en_HK
dc.identifier.scopusauthoridHu, WHC=25932937100en_HK
dc.identifier.scopusauthoridChan, CK=7404813824en_HK
dc.identifier.scopusauthoridXia, HHX=8757161400en_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridFung, FMY=7003833944en_HK
dc.identifier.scopusauthoridTong, TSM=7102587364en_HK
dc.identifier.scopusauthoridHo, VYK=8612107400en_HK
dc.identifier.scopusauthoridLam, SK=7402279473en_HK
dc.identifier.scopusauthoridWong, BCY=7402023340en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats